Table 2.
Demographic characteristics in R/R CLL patients with ibrutinib monotherapy
| CLL patients with secondary hypogammaglobulinemia | CLL patients without secondary hypogammaglobulinemia | p | |
|---|---|---|---|
| Gender | |||
| Female (n,%) | 5, 18.5 | 6, 22.2 | 0.41c |
| Male (n,%) | 4, 14.8 | 12, 44.4 | |
| Bulky disease | |||
| < 5 cm (n,%) | 3, 11.1 | 13, 48.1 | 0.053c |
| ≥ 5 cm (n,%) | 6, 22.2 | 5, 18.5 | |
| Cytogenetics | |||
| del(17p) (n) | 1 | 7 | 0.2c |
| del(11q) (n) | 1 | 2 | 0.54c |
| del(13q) (n) | 2 | 1 | 0.25c |
| Trisomy 12 (n) | – | – | – |
| Normal (n) | 5 | 8 | 0.78c |
| Complex karyotype (n) | 1 | 2 | 1.0c |
| Initiating ibrutinib treatment | |||
| Stage,RAI | 1.0c | ||
| 1 + 2(n) | 5 | 10 | |
| 3 + 4(n) | 4 | 8 | |
| ECOG | 1.0c | ||
| 0 + 1 | 8 | 16 | |
| 2 | 1 | 2 | |
| CIRS | 0.44c | ||
| ≤ 8 | 8 | 16 | |
| > 8 | 1 | 2 | |
| Treatment response* | 0.029c | ||
| CR + PR | 7 | 6 | |
| SD + PD | 2 | 12 | |
| Ibrutinib related Side effects | 9/9 | 2/18 | < 0.001c |
| Number of treatments before ibrutinib | 0.32c | ||
| 1 | 1 | 7 | |
| 2 | 4 | 6 | |
| 3 | 4 | 5 | |
| Before Ibrutinib treatments** | |||
| Chlorambucil (n) | 5 | 10 | 1.0 |
| FCR (n) | 6 | 5 | 0.053 |
| Rituximab-Bendamustin (n) | 7 | 9 | 0.166 |
| R-CHOP (n) | 1 | 1 | 1.0 |
| Rituximab (n) | 2 | 6 | 0.551 |
Bold values indicate the p value 0.05 and below is significant
*CR, complete remission; PD, progressive disease; PR, partial remission; SD, stable disease
**Novel agents such as bcl-2 inhibitors, δ phosphoinositide 3-kinase inhibitors and chimeric antigen receptor T cells prior to ibrutinib could not be used because it is not covered by health insurance system in Turkey
cChi-square, FCR: fludarabine, cyclophosphamide, rituximab, Fischer exact, mMann-Whitney U, R-CHOP: rituximab, cyclophosphamide, doxorubicin, vincristine